Browse the evidence

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) induce significant weight loss (≥10%) and reduce major adverse cardiovascular events (MACE) in patients with obesity, outperforming conventional anti-obesity drugs and lifestyle modification alone.

If you have obesity and are at risk for heart disease, GLP-1 receptor agonists like semaglutide or liraglutide are currently the most effective pharmacological options for achieving significant weight loss (often >10%) and reducing cardiovascular risk. Unlike older weight-loss drugs or lifestyle changes alone, these medications address the hormonal drivers of weight regain and offer specific heart benefits. However, they require long-term use to maintain results, and treatment should be discussed with a healthcare provider to weigh benefits against costs and side effects.

Tirzepatide, a GIP/GLP-1 receptor agonist, achieves unprecedented reductions in HbA1c and clinically significant weight loss in Type 2 Diabetes patients, with a substantial proportion achieving normoglycemia without hypoglycemia.

Tirzepatide is a once-weekly injection that significantly lowers blood sugar and promotes substantial weight loss in people with Type 2 Diabetes, often without causing low blood sugar. It is designed to be started at a low dose and gradually increased to minimize side effects like nausea. This treatment challenges the old view that effective diabetes management requires insulin or causes weight gain.

Multi-receptor incretin drugs (Tirzepatide, Retatrutide, Mazdutide, Survodutide) produce substantial weight loss (>8kg) and glycemic control (HbA1c reduction >1%) in adults with overweight/obesity, with non-diabetic populations showing more pronounced effects than those with type 2 diabetes.

If you have overweight or obesity, multi-receptor incretin drugs like Tirzepatide or Retatrutide are highly effective for significant weight loss (often >10kg) and improving blood sugar control. These benefits are even more pronounced if you do not have type 2 diabetes. While gastrointestinal side effects are common, serious safety risks are not significantly higher than placebo. Consult a healthcare provider to determine if these medications are appropriate for your specific health profile.

Ingesting a 1:1 blend of native whey protein and micellar casein (25g) produces peak plasma leucine and essential amino acid (EAA) concentrations equivalent to whey alone, while sustaining higher EAA levels in the late postprandial period (2-6 hours) compared to whey or casein alone.

If you are consuming protein to support muscle growth, a 1:1 mix of whey and casein (25g) is an effective strategy. It gives you the fast leucine spike of whey to kickstart muscle synthesis, but keeps amino acids in your blood longer than whey alone, potentially supporting muscle building for hours after the meal. You do not need to take both separately; a pre-mixed blend achieves this.

Pharmacological interventions with GLP-1 receptor agonists (e.g., semaglutide 2.4 mg, tirzepatide) and SGLT2 inhibitors promote weight loss and improve glycemic control, contributing to diabetes remission and reduced cardiovascular/renal risks.

If lifestyle changes alone aren't enough to control your diabetes or help you lose weight, ask your doctor about GLP-1 medications like semaglutide or tirzepatide. These are weekly injections that help you lose weight and can put type 2 diabetes into remission for many people. They also protect your heart and kidneys. They are not just 'diet pills' but powerful tools for managing the disease.

Semaglutide 2.4 mg combined with diet and exercise is cost-effective for adults with obesity (BMI ≥ 30 kg/m²) and comorbidities in Portugal, yielding 0.098 QALYs gained at an ICER of 13,459 EUR per QALY compared to diet and exercise alone.

For patients with obesity and comorbidities in Portugal, adding semaglutide 2.4 mg to diet and exercise is a cost-effective strategy that improves quality-adjusted life years compared to diet and exercise alone, particularly for those with BMI ≥ 30 kg/m².

Achieving early weight loss of ≥10% body weight in newly diagnosed type 2 diabetes significantly increases the likelihood of diabetes remission and sustains glycaemic improvements compared to losing <10%.

For newly diagnosed type 2 diabetes, aiming for a 10% body weight loss within the first five years is a critical threshold. This specific magnitude of loss is strongly associated with a 4-fold increase in the chance of achieving diabetes remission and sustained lower HbA1c levels compared to smaller weight losses.

GLP-1 Receptor Agonists (specifically Semaglutide) induce significant weight loss (10-15%) and improve metabolic and endocrine markers (including menstrual regularity and insulin sensitivity) in women with PCOS, although long-term sustainability requires continued treatment.

Semaglutide (a GLP-1 RA) is an effective treatment for women with PCOS who are obese and haven't succeeded with lifestyle changes alone. It promotes significant weight loss (approx. 11-15 kg) and can restore menstrual regularity and improve insulin sensitivity. However, stopping the medication often leads to partial weight regain, suggesting it may need to be a long-term therapy for sustained benefits.

Tirzepatide, a GLP-1/GIP receptor co-agonist, produces superior weight loss and glycemic control compared to selective GLP-1 receptor agonists and insulin in patients with type 2 diabetes.

If you have type 2 diabetes, tirzepatide is a once-weekly injection that lowers blood sugar and helps you lose more weight than older diabetes medications. It is generally well-tolerated, though you may experience gastrointestinal side effects. Discuss with your doctor if this once-weekly option is right for you.

Tirzepatide achieves body weight loss of ≥ 5% significantly faster than semaglutide 1 mg in patients with type 2 diabetes.

If your goal is weight loss alongside blood sugar control, tirzepatide (10 or 15 mg) will likely get you to a 5% body weight reduction in about 12 weeks, which is half the time it takes with semaglutide 1 mg. This benefit persists despite the slower dose escalation schedule required to manage side effects.

Semaglutide 2.4 mg administered subcutaneously once-weekly produces significant body weight reduction (mean 12.2 kg or 11.8%) and improves cardiometabolic parameters in adults with obesity, with real-world evidence confirming efficacy similar to randomized controlled trials.

Semaglutide 2.4mg once weekly is a highly effective treatment for obesity, producing an average 12kg weight loss when combined with lifestyle changes. Real-world data confirms it works as well as in clinical trials. Be aware of common side effects like nausea, which often subside, and discuss cost-effectiveness with your provider as it varies by region and insurance.

Tirzepatide, a dual GLP-1/GIP receptor agonist, produces significantly greater body weight reduction (up to 20.9% at 15mg) compared to semaglutide and other GLP-1 agonists in patients with obesity, with real-world studies confirming superior efficacy.

Tirzepatide (up to 15mg once weekly) is the most effective current pharmacological treatment for obesity, producing up to 21% weight loss. Real-world data shows it outperforms semaglutide. Discuss side effects like nausea with your provider, and consider cost-effectiveness as data is still emerging.

Structured aerobic, resistance, or combined exercise training for at least 12 weeks significantly improves glycemic control (HbA1c reduction of 0.51-0.73%) in patients with Type 2 Diabetes.

Engage in structured exercise (aerobic, resistance, or both) for at least 12 weeks. Aim for more than 2.5 hours per week for maximum blood sugar benefits. Start with lower intensities if new to exercise.

Regular physical activity reduces cardiovascular mortality and all-cause mortality in patients with Type 2 Diabetes.

Engage in regular, sufficient physical activity to reduce your risk of death from heart disease or other causes.

Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, produces superior mean weight loss (up to 24.2%) and metabolic improvements compared to placebo and existing dual agonists in phase 2 trials for obesity and type 2 diabetes.

Retatrutide is a once-weekly injection that targets three hormones to significantly reduce body weight and improve blood sugar control. In clinical trials, it led to an average 24% weight loss in people with obesity over 48 weeks. Common side effects like nausea are manageable with dose titration. It is currently in phase 3 trials for broader approval.

High-dose GLP-1 receptor agonists (e.g., semaglutide 2.4mg) and dual GLP-1/GIP agonists (e.g., tirzepatide) are effective for treating prediabetes by inducing significant weight loss (15-20%), which reduces insulin resistance and lowers diabetes risk.

If you have prediabetes and struggle to lose weight, high-dose GLP-1 or GLP-1/GIP injections (like semaglutide or tirzepatide) are highly effective. They cause significant weight loss (15-20%), which fixes the underlying insulin resistance and reduces diabetes risk. You likely need to stay on them long-term to keep the weight off.

Tirzepatide induces significant weight reduction in individuals with obesity caused by pathogenic MC4R mutations, achieving efficacy comparable to non-carriers.

If you have obesity caused by an MC4R mutation, tirzepatide is a highly effective treatment option. Clinical data shows you will likely lose a significant amount of weight (around 18%) over 72 weeks, similar to people without this genetic mutation. Because lifestyle changes alone are often insufficient for this specific genetic profile, pharmacological intervention with tirzepatide is recommended to manage severe obesity and its complications.

Carrying the T allele of the GLP1R missense variant rs10305420 (p.Pro7Leu) significantly increases weight loss efficacy in patients treated with GLP-1 receptor agonists, adding approximately 0.76 kg of weight loss per allele copy.

If you are taking a GLP-1 medication like semaglutide or tirzepatide, your genetics play a role in how much weight you lose. Specifically, a common genetic variant (rs10305420) is linked to better weight loss results. While this genetic effect is modest (adding less than 1 kg on average), it is a real biological factor. This suggests that genetic testing could eventually help doctors predict who will respond best to which drug, allowing for more personalized treatment plans rather than a one-size-fits-all approach.

Once-weekly efpeglenatide significantly reduces HbA1c and body weight in patients with type 2 diabetes and obesity, with a safety profile characterized by mild-to-moderate gastrointestinal side effects and low hypoglycemia risk.

Efpeglenatide is a once-weekly (or monthly) injection that helps lower blood sugar and lose weight in people with type 2 diabetes and obesity. It is generally well-tolerated, with common side effects like nausea being mild and temporary. It offers a convenient alternative to daily medications and has cardiovascular benefits for high-risk patients.

Cagrilintide, a long-acting amylin analogue, produces dose-dependent weight loss in adults with obesity, with the highest dose (4.5 mg) showing greater weight loss than Liraglutide 3.0 mg.

Cagrilintide is a once-weekly injection that mimics the hormone amylin to reduce appetite and slow digestion. In a 26-week trial, the highest dose (4.5 mg) led to an average 10.8% weight loss, outperforming Liraglutide 3.0 mg. It is currently in Phase 2 development for adults with obesity.

Orlistat reduces the incidence of type 2 diabetes in individuals with prediabetes or impaired glucose tolerance by approximately 37% over four years compared to placebo when combined with lifestyle changes.

If you are overweight and have prediabetes, adding orlistat (120mg with meals) to your lifestyle changes can significantly lower your risk of developing full-blown type 2 diabetes compared to lifestyle changes alone. Be mindful of your fat intake to minimize gastrointestinal side effects.

Anti-obesity medications (AOMs), particularly GLP-1 and dual GIP/GLP-1 agonists, produce significant weight loss (5-20%+) and should be continued long-term as disease-modifying agents rather than short-term aids.

If you have obesity or overweight with related health issues, talk to your doctor about long-term medication options like GLP-1 agonists. These are not quick fixes but chronic disease treatments. Expect to start with a low dose to minimize stomach issues and increase it slowly. You must combine this with lifestyle changes for the best results, and do not stop the medication once you reach your goal, as stopping often leads to regaining the weight.

Gut hormone-based pharmacotherapies (GLP-1RAs, amylin analogues, and multi-agonists) produce clinically significant weight loss (≥10-15%) and improve cardiometabolic health, effectively closing the treatment gap between lifestyle interventions and bariatric surgery.

For individuals with obesity who have not achieved sufficient weight loss through lifestyle changes alone, gut hormone-based medications (like semaglutide or tirzepatide) offer a clinically effective treatment option that can produce 10-15% or more weight loss. These treatments work by targeting the body's natural appetite-regulating systems, mimicking the effects of bariatric surgery to a degree, and improving metabolic health. While side effects like nausea are common, they often subside with dose titration, and new oral formulations are emerging to address injection aversion.

Combination therapies targeting multiple gut hormone pathways (e.g., GLP-1 + Amylin, GLP-1 + GIP, GLP-1 + GIP + Glucagon) show superior weight loss efficacy compared to monotherapies, approaching the magnitude of weight loss seen after bariatric surgery.

For patients who do not achieve sufficient weight loss with single-agent GLP-1 therapy, combination treatments (like CagriSema or Tirzepatide) offer a powerful alternative. These drugs target multiple hormonal pathways simultaneously, resulting in greater weight loss (up to 17% or more in trials) than monotherapies alone. This approach narrows the gap between medication and surgery, offering a viable option for those with severe obesity.